|
|
|
| Fecal microbiota transplantation has therapeutic effects on chronic hepatits B patients via altering composition of gut microbiota |
| Jia-Min Lou a , b , Zhi-Gang Ren a , b , Ang Li a , b , Ben-Chen Rao a , b , Zu-Jiang Yu a , b , ∗ |
a Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou 450052, China
b Gene Hospital of Henan Province, Precision Medicine Center, the First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
∗ Corresponding author at: Department of Infectious Diseases, the First Affiliated Hospital of Zhengzhou University, No. 1 Jianshe East Road, Zhengzhou 450052, China.
E-mail address: johnyuem@zzu.edu.cn (Z.-J. Yu). |
|
|
|
|
Abstract Chronic hepatits B (CHB) is an increasingly disturbing public health issue worldwide. Currently, interferon and oral antiviral drugs such as entecavir (ETV) or tenofovir disoproxil fumarate (TDF) are two internationally recognized drugs for the treatment of CHB. However, the HBeAg clearance or seroconversion rate is low even in patients with long-term antiviral therapy. Many patients have to increase the dosage of antiviral therapy drugs [1] . Intestinal microorganisms are confirmed to play an important role in the pathogenesis of different chronic liver diseases including CHB, and fecal microbiota transplantation (FMT) may be a novel treatment strategy for CHB.
|
|
|
|
|
|
|
|
|
2020, Vol. 19 
